Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1954 1
1955 1
1956 2
1957 3
1958 3
1959 5
1960 5
1961 5
1962 6
1963 9
1964 12
1965 5
1966 7
1967 7
1968 8
1969 9
1970 13
1971 10
1972 8
1973 2
1974 11
1975 12
1976 11
1977 19
1978 22
1979 22
1980 31
1981 32
1982 30
1983 25
1984 43
1985 57
1986 62
1987 66
1988 64
1989 62
1990 60
1991 65
1992 75
1993 103
1994 78
1995 88
1996 114
1997 116
1998 101
1999 94
2000 109
2001 117
2002 135
2003 117
2004 142
2005 163
2006 201
2007 198
2008 202
2009 177
2010 218
2011 225
2012 235
2013 230
2014 289
2015 277
2016 299
2017 340
2018 333
2019 349
2020 391
2021 339
2022 327
2023 293
2024 254
2025 294
2026 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,102 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, Tseng LM, Chung CF, Huang CS, Kim JH, Chiu JWY, Yamashita T, Li W, Egorov A, Nishijima S, Nakatani S, Nishiyama Y, Sugihara M, Cortés J, Im SA. Iwata H, et al. Among authors: yamashita t. Cancer Sci. 2024 Sep;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9. Cancer Sci. 2024. PMID: 38979893 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Saura C, Modi S, Krop I, Park YH, Kim SB, Tamura K, Iwata H, Tsurutani J, Sohn J, Mathias E, Liu Y, Cathcart J, Singh J, Yamashita T. Saura C, et al. Among authors: yamashita t. Ann Oncol. 2024 Mar;35(3):302-307. doi: 10.1016/j.annonc.2023.12.001. Epub 2023 Dec 11. Ann Oncol. 2024. PMID: 38092229 Free PMC article. Clinical Trial.
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Mukohara T, et al. Among authors: yamashita t. Nat Med. 2024 Aug;30(8):2242-2250. doi: 10.1038/s41591-024-03060-0. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38824244 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, Park YH, Rimawi MF, Saura C, Schneeweiss A, Toi M, Chae YS, Kemal Y, Chaudhari M, Şendur MAN, Yamashita T, Casalnuovo M, Danso MA, Liu J, Shetty J, Herbolsheimer P, Loibl S; DESTINY-Breast09 Trial Investigators. Tolaney SM, et al. Among authors: yamashita t. N Engl J Med. 2025 Oct 29. doi: 10.1056/NEJMoa2508668. Online ahead of print. N Engl J Med. 2025. PMID: 41160818
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.
Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Yamashita T, et al. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17. Breast Cancer. 2024. PMID: 38884900 Free PMC article. Clinical Trial.
Endothelial dysfunction drives atherosclerotic plaque macrophage-dependent abdominal aortic aneurysm formation.
Thayaparan D, Emoto T, Khan AB, Besla R, Hamidzada H, El-Maklizi M, Sivasubramaniyam T, Vohra S, Hagerman A, Nejat S, Needham-Robbins CE, Wang T, Lindquist M, Botts SR, Schroer SA, Taniguchi M, Inoue T, Yamanaka K, Cui H, Al-Chami E, Zhang H, Althagafi MG, Michalski A, McGrath JJC, Cass SP, Luong D, Suzuki Y, Li A, Abow A, Heo R, Pacheco S, Chen E, Chiu F, Byrne J, Furuyashiki T, Husain M, Libby P, Okada K, Howe KL, Heximer SP, Yamashita T, Wang B, Rubin BB, Cybulsky MI, Roy J, Williams JW, Crome SQ, Epelman S, Hirata KI, Stampfli MR, Robbins CS. Thayaparan D, et al. Among authors: yamashita t. Nat Immunol. 2025 May;26(5):706-721. doi: 10.1038/s41590-025-02132-8. Epub 2025 Apr 22. Nat Immunol. 2025. PMID: 40263614
Left atrial single-cell transcriptomics reveals amphiregulin as a surrogate marker for atrial fibrillation.
Suzuki Y, Emoto T, Sato S, Yoshida T, Shoda M, Endoh H, Nagao M, Hamana T, Inoue T, Hayashi T, Nitta E, Konishi H, Kiuchi K, Takami M, Imamura K, Taniguchi M, Inoue M, Nakamura T, Sonoda Y, Takahara H, Nakasone K, Yamamoto K, Tani K, Iwai H, Nakanishi Y, Yonehara S, Murakami A, Toh R, Ohkawa T, Furuyashiki T, Nitta R, Yamashita T, Hirata KI, Fukuzawa K. Suzuki Y, et al. Among authors: yamashita t. Commun Biol. 2024 Dec 2;7(1):1601. doi: 10.1038/s42003-024-07308-w. Commun Biol. 2024. PMID: 39622943 Free PMC article.
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA. André F, et al. Among authors: yamashita t. Ann Oncol. 2024 Dec;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347. Epub 2024 Sep 5. Ann Oncol. 2024. PMID: 39241960 Free article.
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.
Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Ohba A, et al. Among authors: yamashita t. J Clin Oncol. 2025 Nov;43(31):3345-3354. doi: 10.1200/JCO.24.00936. Epub 2025 Jul 28. J Clin Oncol. 2025. PMID: 40720715 Free PMC article. Clinical Trial.
Sucrose-preferring gut microbes prevent host obesity by producing exopolysaccharides.
Shimizu H, Miyamoto J, Hisa K, Ohue-Kitano R, Takada H, Yamano M, Nishida A, Sasahara D, Masujima Y, Watanabe K, Nishikawa S, Takahashi S, Ikeda T, Nakajima Y, Yoshida N, Matsuzaki C, Kageyama T, Hayashi I, Matsuki A, Akashi R, Kitahama S, Ueyama M, Murakami T, Inuki S, Irie J, Satoh-Asahara N, Toju H, Mori H, Nakaoka S, Yamashita T, Toyoda A, Yamamoto K, Ohno H, Katayama T, Itoh H, Kimura I. Shimizu H, et al. Among authors: yamashita t. Nat Commun. 2025 Jan 29;16(1):1145. doi: 10.1038/s41467-025-56470-0. Nat Commun. 2025. PMID: 39880823 Free PMC article.
7,102 results